November 14, 2026
$RichWire Markets and money, explained simply
LIVE
Anthropic IPO Set for Thursday as Investors Eye AI Sector Shift Microsoft Outage Disrupts Courts, Hospitals, and Government Services Globally Federal Realty Maintain Its Dividend King Status for Everyday Investors McGraw Hill Q2 Earnings: Digital Subscriptions and AI Integration Drive Growth SBC Medical Group Shares Jump 37% on Strong Earnings and New AI Partnership U.S. Aviation Grounded and Cloud Services Disrupted in Back-to-Back Infrastructure Failures Micron and Qualcomm Balance Growth and Risk Heading Into 2027 Denali Therapeutics Reports Strong Early Adoption and $7.8 Million Revenue for AVLAYAH Dutch Bros and Wendy's Highlight Distinct Growth and Income Strategies for Restaurant Investors Bob's Discount Furniture Reports Q3 Revenue Growth Amid Retail Expansion Cresud Expands Planted Crop Area by 3% amid Favorable El Niño Outlook FAA Ground Stop Halts US Departures After Massive Telecommunications Failure Anthropic IPO Set for Thursday as Investors Eye AI Sector Shift Microsoft Outage Disrupts Courts, Hospitals, and Government Services Globally Federal Realty Maintain Its Dividend King Status for Everyday Investors McGraw Hill Q2 Earnings: Digital Subscriptions and AI Integration Drive Growth SBC Medical Group Shares Jump 37% on Strong Earnings and New AI Partnership U.S. Aviation Grounded and Cloud Services Disrupted in Back-to-Back Infrastructure Failures Micron and Qualcomm Balance Growth and Risk Heading Into 2027 Denali Therapeutics Reports Strong Early Adoption and $7.8 Million Revenue for AVLAYAH Dutch Bros and Wendy's Highlight Distinct Growth and Income Strategies for Restaurant Investors Bob's Discount Furniture Reports Q3 Revenue Growth Amid Retail Expansion Cresud Expands Planted Crop Area by 3% amid Favorable El Niño Outlook FAA Ground Stop Halts US Departures After Massive Telecommunications Failure

Denali Therapeutics Reports Strong Early Adoption and $7.8 Million Revenue for AVLAYAH

🏢 Companies 1 min read 👁 0

Denali Therapeutics highlighted positive early momentum for its AVLAYAH launch during a recent healthcare conference, posting $7.8 million in second-quarter commercial revenue.

Denali Therapeutics Reports Strong Early Adoption and $7.8 Million Revenue for AVLAYAH🏢Companies

Photo: Seeking Alpha

Key points

  • AVLAYAH generated $7.8 million in commercial revenue in its second quarter on the market.
  • Commercial insurance coverage stands at roughly 70% of lives.
  • State Medicaid programs across 20 states have established coverage for the product.

Denali Therapeutics Inc. shared updates on the commercial rollout of AVLAYAH during a presentation at the Stifel Healthcare Conference, pointing to solid early interest from both clinical experts and patient families. Chief Scientific Officer Joe Lewcock discussed the initial traction with conference moderator Paul Matteis from Stifel Nicolaus Canada.

According to company executives, the product launch has met expectations driven by coordination among physicians, families, and insurance providers. Denali reported that approximately 70% of commercial lives currently have coverage for the treatment, alongside 20 state Medicaid programs providing access.

This market access translated to $7.8 million in commercial revenue during the second quarter following the product's launch. Management indicated that the collaborative reimbursement environment has been instrumental in supporting the early rollout phase.

What to watch next: Monitor upcoming clinical pipeline updates and further insurance coverage expansion for the treatment. Residues of broader adoption trends will be critical for future quarterly results.

Source Seeking Alpha — seekingalpha.com/article/4968099-denali-therapeutics-inc-dnli-presents-… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.